Advertisement

Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls

      Highlights

      • Pregnant breast cancer patients (PrBC) have similar survival as non-pregnant controls.
      • Pregnancy does not impact the effectiveness of chemotherapy for breast cancer.
      • This cohort study supports initiation of chemotherapy for PrBC when indicated.

      Abstract

      Background

      A diagnosis of breast cancer during pregnancy (PrBC) does not impact prognosis if standard treatment is offered. However, caution is warranted as gestational changes in pharmacokinetics may lead to reduced chemotherapy concentration.

      Methods

      Survival of PrBC patients treated with chemotherapy during pregnancy was compared to non-pregnant breast cancer patients treated with chemotherapy, diagnosed after 2000, excluding patients older than 45 years or with a postpartum diagnosis. The data was registered in two multicenter registries (the International Network of Cancer, Infertility and Pregnancy and the German Breast Group). Cox proportional hazards regression was used to compare disease-free (DFS) and overall survival (OS) between both groups, adjusting for age, stage, grade, hormone receptor status, human epidermal growth factor 2 status and histology, weighted by propensity scoring to account for the differences in baseline characteristics between pregnant patients and controls.

      Results

      In total, 662 pregnant and 2081 non-pregnant patients were selected. Pregnant patients were more likely to have stage II breast cancer (60.1% vs 56.1%, p = 0.035), grade 3 tumors (74.0% vs 62.2%, p < 0.001), hormone receptor-negative tumors (48.4% vs 34.0%, p < 0.001) or triple-negative breast cancer (38.9% vs 26.9%, p < 0.001). Median follow-up was 66 months. In multivariable analysis, DFS and OS were comparable for pregnant and non-pregnant patients (DFS: HR 1.02, 95% CI 0.82–1.27, p = 0.83; OS: HR 1.08, 95% CI 0.81–1.45, p = 0.59).

      Conclusion

      Outcome of women with breast cancer treated with chemotherapy during pregnancy is comparable to young non-pregnant women. These results support chemotherapy for PrBC when indicated.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Amant F.
        • Lefrère H.
        • Borges V.F.
        • et al.
        The definition of pregnancy-associated breast cancer is outdated and should no longer be used.
        Lancet Oncol. 2021; 22: 753-754
        • Loibl S.
        • Schmidt A.
        • Gentilini O.
        • et al.
        Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients.
        JAMA Oncol. 2015; 1: 1145-1153
        • Stensheim H.
        • Moller B.
        • van Dijk T.
        • Fossa S.D.
        Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study.
        J Clin Oncol. 2009; 27: 45-51
        • Amant F.
        • von Minckwitz G.
        • Han S.N.
        • et al.
        Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.
        J Clin Oncol. 2013; 31: 2532-2539
        • Abduljalil K.
        • Furness P.
        • Johnson T.N.
        • Rostami-Hodjegan A.
        • Soltani H.
        Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.
        Clin Pharmacokinet. 2012; 51: 365-396
        • van Hasselt J.G.
        • van Calsteren K.
        • Heyns L.
        • et al.
        Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
        Ann Oncol. 2014; 25: 2059-2065
        • Janssen J.M.
        • Van Calsteren K.
        • Dorlo T.P.C.
        • et al.
        Population pharmacokinetics of docetaxel, paclitaxel, doxorubicin and epirubicin in pregnant women with cancer: a study from the international Network of cancer, infertility and pregnancy (INCIP).
        Clin Pharmacokinet. 2021; 60: 775-784
        • Loibl S.
        • Han S.N.
        • von Minckwitz G.
        • et al.
        Treatment of breast cancer during pregnancy: an observational study.
        Lancet Oncol. 2012; 13: 887-896
        • Ploquin A.
        • Pistilli B.
        • Tresch E.
        • et al.
        5-year overall survival after early breast cancer diagnosed during pregnancy: a retrospective case-control multicentre French study.
        Eur J Cancer. 2018; 95: 30-37
        • Litton J.K.
        • Warneke C.L.
        • Hahn K.M.
        • et al.
        Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer.
        Oncol. 2013; 18: 369-376
        • Halaska M.J.
        • Pentheroudakis G.
        • Strnad P.
        • et al.
        Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study.
        Breast J. 2009; 15: 461-467
        • Lefrere H.
        • Floris G.
        • Schmidt M.K.
        • et al.
        Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome.
        Eur J Cancer. 2021; 155: 13-24
        • Austin P.C.
        An introduction to propensity score methods for reducing the effects of confounding in observational studies.
        Multivariate Behav Res. 2011; 46: 399-424
      1. IVEware: imputation and variance estimation software, version 0.3. at https://www.src.isr.umich.edu/software/.

        • Bines J.
        • Earl H.
        • Buzaid A.C.
        • Saad E.D.
        Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?.
        Ann Oncol. 2014; 25: 1079-1085
        • de Haan J.
        • Verheecke M.
        • Van Calsteren K.
        • et al.
        Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients.
        Lancet Oncol. 2018; 19: 337-346
        • Amant F.
        • Vandenbroucke T.
        • Verheecke M.
        • et al.
        Pediatric outcome after maternal cancer diagnosed during pregnancy.
        N Engl J Med. 2015; 373: 1824-1834
        • Vandenbroucke T.
        • Verheecke M.
        • van Gerwen M.
        • et al.
        Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy.
        Eur J Cancer. 2020; 138: 57-67
        • Maggen C.
        • Dierickx D.
        • Lugtenburg P.
        • et al.
        Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study.
        Lancet Haematol. 2019; 6: e551-e561
        • Zagouri F.
        • Sergentanis T.N.
        • Chrysikos D.
        • Papadimitriou C.A.
        • Dimopoulos M.A.
        • Bartsch R.
        Trastuzumab administration during pregnancy: a systematic review and meta-analysis.
        Breast Cancer Res Treat. 2013; 137: 349-357
        • Perez E.A.
        • Suman V.J.
        • Davidson N.E.
        • et al.
        Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
        J Clin Oncol. 2011; 29: 4491-4497
        • Piccart-Gebhart M.J.
        • Procter M.
        • Leyland-Jones B.
        • et al.
        Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
        N Engl J Med. 2005; 353: 1659-1672
        • Cameron D.
        • Piccart-Gebhart M.J.
        • Gelber R.D.
        • et al.
        11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
        Lancet. 2017; 389: 1195-1205
        • Froehlich K.
        • Schmidt A.
        • Heger J.I.
        • et al.
        Breast cancer, placenta and pregnancy.
        Eur J Cancer. 2019; 115: 68-78
        • Yager J.D.
        • Davidson N.E.
        Estrogen carcinogenesis in breast cancer.
        N Engl J Med. 2006; 354: 270-282